{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T20:35:01Z","timestamp":1786739701841,"version":"build-2736575974"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,1]]},"abstract":"<jats:sec>\n                    <jats:title>PURPOSE:<\/jats:title>\n                    <jats:p>This prospective study evaluates whether rituximab is a safe and potentially effective treatment for nonparaneoplastic autoimmune retinopathy (npAIR).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>MATERIALS AND METHODS:<\/jats:title>\n                    <jats:p>Five npAIR patients were enrolled in a Phase I\/II, prospective, nonrandomized, open-label, single-center study. All patients received a cycle of 1000 mg intravenous rituximab at weeks 0 and 2, with a second cycle of rituximab 6 to 9 months later. Clinical evaluation was performed at baseline, 6 and 12 weeks after each rituximab cycle, and then every 3 months for a total duration of 18 months. The primary outcome for this study was treatment success based on visual field and full-field electroretinography at 6 months. The secondary outcomes included treatment success at months 12 and 18, drug-related adverse events, changes in visual symptoms, and changes in quality of life.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS:<\/jats:title>\n                    <jats:p>Two patients met criteria for treatment success: one based solely on electroretinography and the other based solely on visual field area, but treatment success was not sustained. Clinical response over the course of the 18-month study showed disease stabilization in three patients and treatment failure in two patients. There were no severe drug-related adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION:<\/jats:title>\n                    <jats:p>This is the first clinical trial prospectively evaluating the effect of rituximab in npAIR and, although rituximab was well tolerated, there was no clear-cut clinical improvement conferred by B cell depletion with rituximab.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/tjo.tjo_32_20","type":"journal-article","created":{"date-parts":[[2020,7,26]],"date-time":"2020-07-26T08:17:23Z","timestamp":1595751443000},"page":"64-70","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":10,"title":["Rituximab for autoimmune retinopathy"],"prefix":"10.4103","volume":"11","author":[{"given":"Karen R.","family":"Armbrust","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Austin R.","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett G.","family":"Jeffrey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patti","family":"Sherry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Nida","family":"Sen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-8-20240830","first-page":"1936","article-title":"Two mouse models for recoverin-associated autoimmune retinopathy","volume":"16","author":"Lu","year":"2010","journal-title":"Mol Vis"},{"key":"R2-8-20240830","doi-asserted-by":"crossref","first-page":"e69506","DOI":"10.1371\/journal.pone.0069506","article-title":"Serum TRPM1 autoantibodies from melanoma associated retinopathy patients enter retinal on-bipolar cells and attenuate the electroretinogram in mice","volume":"8","author":"Xiong","year":"2013","journal-title":"PLoS One"},{"key":"R3-8-20240830","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.ajo.2016.05.013","article-title":"Consensus on the diagnosis and management of nonparaneoplastic autoimmune retinopathy using a modified Delphi approach","volume":"168","author":"Fox","year":"2016","journal-title":"Am J Ophthalmol"},{"key":"R4-8-20240830","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.ajo.2013.09.019","article-title":"Autoimmune retinopathy","volume":"157","author":"Grange","year":"2014","journal-title":"Am J Ophthalmol"},{"key":"R6-8-20240830","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1111\/j.1600-6143.2006.01288.x","article-title":"Rituximab, an anti-cd20 monoclonal antibody: History and mechanism of action","volume":"6","author":"Pescovitz","year":"2006","journal-title":"Am J Transplant"},{"key":"R7-8-20240830","doi-asserted-by":"crossref","first-page":"322","DOI":"10.3109\/09273941003802379","article-title":"A case of autoimmune retinopathy associated with thyroid carcinoma","volume":"18","author":"Mahdi","year":"2010","journal-title":"Ocul Immunol Inflamm"},{"key":"R8-8-20240830","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1016\/j.jcjo.2012.11.010","article-title":"Intravenous rituximab for the treatment of cancer-associated retinopathy","volume":"48","author":"Or","year":"2013","journal-title":"Can J Ophthalmol"},{"key":"R9-8-20240830","doi-asserted-by":"crossref","first-page":"e101","DOI":"10.1016\/j.jcjo.2015.08.009","article-title":"Rituximab treatment for nonparaneoplastic autoimmune retinopathy","volume":"50","author":"Fox","year":"2015","journal-title":"Can J Ophthalmol"},{"key":"R10-8-20240830","doi-asserted-by":"crossref","first-page":"377","DOI":"10.2147\/OPTH.S120162","article-title":"Rituximab as a monotherapy or in combination therapy for the treatment of non-paraneoplastic autoimmune retinopathy","volume":"11","author":"Maleki","year":"2017","journal-title":"Clin Ophthalmol"},{"key":"R11-8-20240830","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ajo.2017.04.019","article-title":"Outcomes in autoimmune retinopathy patients treated with rituximab","volume":"180","author":"Davoudi","year":"2017","journal-title":"Am J Ophthalmol"},{"key":"R12-8-20240830","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/S0161-6420(03)00253-7","article-title":"Variability of full-field electroretinogram responses in subjects without diffuse photoreceptor cell disease","volume":"110","author":"Grover","year":"2003","journal-title":"Ophthalmology"},{"key":"R13-8-20240830","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1097\/00006982-200512000-00010","article-title":"Short-term intervisit variability of erg amplitudes in normal subjects and patients with retinitis pigmentosa","volume":"25","author":"Fishman","year":"2005","journal-title":"Retina"},{"key":"R14-8-20240830","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1167\/tvst.3.5.5","article-title":"Test \u2013 Retest intervisit variability of functional and structural parameters in X-linked retinoschisis","volume":"3","author":"Jeffrey","year":"2014","journal-title":"Transl Vis Sci Technol"},{"key":"R15-8-20240830","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1001\/archopht.119.7.1050","article-title":"Development of the 25-item National Eye Institute Visual Function Questionnaire","volume":"119","author":"Mangione","year":"2001","journal-title":"Arch Ophthalmol"},{"key":"R16-8-20240830","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s13023-017-0680-7","article-title":"Efficacy of rituximab in non-paraneoplastic autoimmune retinopathy","volume":"12","author":"Boudreault","year":"2017","journal-title":"Orphanet J Rare Dis"},{"key":"R17-8-20240830","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.ophtha.2003.05.036","article-title":"Waldenstr\u00f6m's macroglobulinemia-associated retinopathy","volume":"111","author":"Sen","year":"2004","journal-title":"Ophthalmology"},{"key":"R18-8-20240830","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1111\/aos.12939","article-title":"Prevalence and clinical impact of antiretinal antibodies in uveitis","volume":"94","author":"Ten Berge","year":"2016","journal-title":"Acta Ophthalmol"},{"key":"R19-8-20240830","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1001\/jamaophthalmol.2013.574","article-title":"Concordance of antiretinal antibody testing results between laboratories in autoimmune retinopathy","volume":"131","author":"Faez","year":"2013","journal-title":"JAMA Ophthalmol"},{"key":"R20-8-20240830","doi-asserted-by":"crossref","first-page":"xv","DOI":"10.1016\/j.ajo.2017.06.006","article-title":"Rituximab for the treatment of autoimmune retinopathy","volume":"180","author":"Forooghian","year":"2017","journal-title":"Am J Ophthalmol"},{"key":"R21-8-20240830","doi-asserted-by":"crossref","first-page":"20","DOI":"10.2174\/1874364100903010020","article-title":"Autoimmune retinopathy in systemic lupus erythematosus: Histopathologic features","volume":"3","author":"Cao","year":"2009","journal-title":"Open Ophthalmol J"},{"key":"R22-8-20240830","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1097\/IAE.0000000000000119","article-title":"Autoimmune retinopathy and antiretinal antibodies: A review","volume":"34","author":"Grewal","year":"2014","journal-title":"Retina"}],"container-title":["Taiwan Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/tjo.tjo_32_20","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T19:31:32Z","timestamp":1786735892000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/tjo.tjo_32_20"}},"subtitle":["Results of a Phase I\/II clinical trial"],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.4103\/tjo.tjo_32_20","relation":{},"ISSN":["2211-5056"],"issn-type":[{"value":"2211-5056","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]}}}